TCR2 Therapeutics Inc.
TCRR · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29 | $26 | $25 | $26 |
| G&A Expenses | $8 | $6 | $6 | $6 |
| SG&A Expenses | $8 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $37 | $32 | $31 | $32 |
| Operating Income | -$42 | -$61 | -$31 | -$32 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $0 |
| Pre-Tax Income | -$40 | -$60 | -$31 | -$31 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40 | -$61 | -$31 | -$32 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -1.56 | -0.79 | -0.82 |
| % Growth | 34% | -97.5% | 3.7% | – |
| EPS Diluted | -1.03 | -1.56 | -0.79 | -0.82 |
| Weighted Avg Shares Out | 39 | 39 | 39 | 39 |
| Weighted Avg Shares Out Dil | 39 | 39 | 39 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $7 | $0 | $0 | $0 |
| Depreciation & Amortization | $9 | $60 | $1 | $1 |
| EBITDA | -$33 | -$2 | -$30 | -$30 |
| % Margin | – | – | – | – |